Study: NCT03457701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEPO
Description: rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEPO
Description: rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEPO
Description: rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEPO
Description: rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (57Fe)
Description: 57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (57Fe)
Description: 57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (57Fe)
Description: 57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (57Fe)
Description: 57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (58Fe)
Description: 58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (58Fe)
Description: 58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (58Fe)
Description: 58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing the stable iron isotope (58Fe)
Description: 58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).